These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22345334)

  • 1. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
    Wilby KJ; Greanya ED; Ford JA; Yoshida EM; Partovi N
    Ann Hepatol; 2012; 11(2):179-85. PubMed ID: 22345334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
    Wilby KJ; Partovi N; Ford JA; Greanya E; Yoshida EM
    Can J Gastroenterol; 2012 Apr; 26(4):205-10. PubMed ID: 22506260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
    Tungol A; Rademacher K; Schafer JA
    J Manag Care Pharm; 2011 Nov; 17(9):685-94. PubMed ID: 22050393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
    Talavera Pons S; Lamblin G; Boyer A; Sautou V; Abergel A
    Eur J Clin Pharmacol; 2014 Jul; 70(7):775-89. PubMed ID: 24817413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
    Wire MB; Fang L; Hussaini A; Kleha JF; Theodore D
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6704-9. PubMed ID: 25155600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of drug-drug interactions in the DAA era.
    Back D; Else L
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S343-8. PubMed ID: 24091114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M; Silva M; Spooner L; Comee MK; Malloy M
    Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
    Lam JT; Jacob S
    Am J Health Syst Pharm; 2012 Dec; 69(24):2135-9. PubMed ID: 23230035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic interactions of telaprevir with other drugs].
    Berenguer Berenguer J; González-García J
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():37-48. PubMed ID: 24063902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systematic review of new protease inhibitors interactions: telaprevir and boceprevir].
    Izquierdo-García E; Escobar-Rodríguez I
    Farm Hosp; 2012; 36(6):469-82. PubMed ID: 23461440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].
    Delaborde L; Logerot S; Fonrose X
    Therapie; 2014; 69(6):491-7. PubMed ID: 25320939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors].
    Ruiz Ramos J; Romero Hernández I; Marrero Álvarez P; Marqués Miñana MR; Fernández Megía MJ; Poveda Andrés JL
    Gastroenterol Hepatol; 2014 Dec; 37(10):558-63. PubMed ID: 24951300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.